MDR1 101: The Mutation That Can Kill Your Dog

Loperamide, the active ingredient of over-the-counter Imodium, is the textbook example. Given at ordinary anti-diarrheal doses to a Collie carrying two copies of the MDR1 mutation, it has caused severe neurological toxicity (Sartor and colleagues, Journal of Veterinary Internal Medicine, 2004), and Washington State University now advises that it be avoided in every dog with the mutation. A DNA test, sold by WSU for $70, would have told that dog's owner that loperamide would cross its blood-brain barrier in dangerous concentrations.

Loperamide is not an isolated case: ivermectin, vincristine, digoxin and several other drugs have produced the same kind of reaction in dogs with the mutation. The MDR1 mutation is among the most clinically significant genetic variants in veterinary medicine, yet awareness remains frustratingly low among both pet owners and veterinary professionals.

The Molecular Biology of MDR1

The MDR1 gene, formally designated ABCB1 in genetic databases, encodes a protein called P-glycoprotein (P-gp). This protein functions as an ATP-dependent efflux pump, actively transporting substrates out of cells. P-gp is expressed throughout the body but is particularly concentrated in the blood-brain barrier, intestinal epithelium, liver, and kidneys.

In dogs with normal MDR1 function, P-gp prevents certain lipophilic compounds from accumulating in brain tissue. The protein recognizes specific molecular structures and pumps them back into the bloodstream before they can cross into the central nervous system. This protective mechanism evolved to prevent neurotoxic plant compounds from reaching the brain.

The 4-Base Pair Deletion

The MDR1 mutation is a 4-base pair deletion (nt230(del4)) in exon 4 of the ABCB1 gene. This deletion causes a frameshift that introduces a premature stop codon at amino acid 91. The resulting protein is severely truncated, containing only about 7% of the normal 1,280 amino acids, and is completely non-functional.

What makes this mutation particularly dangerous is its recessive nature combined with the fact that even heterozygous dogs (carriers with one normal and one mutant copy) show reduced P-gp activity. Research from Washington State University's Clinical Pharmacology Laboratory and other research groups have shown that N/M dogs have an intermediate phenotype: reduced P-gp function that makes them more sensitive to substrate drugs than N/N dogs, though less affected than M/M individuals.

Breed Prevalence Data

The MDR1 mutation originated in a common ancestor of modern herding breeds, likely in the British Isles before breed registries were established. The mutation spread as these ancestral dogs were used to found multiple distinct breeds. Population genetics studies have mapped its distribution; the first column below gives Washington State University's approximate breed frequencies:

Breed Dogs With at Least One Copy (WSU) What the Studies Add
Collie (Rough/Smooth) About 70% 35% M/M and 42% N/M in a 2002 study of 40 Collies
Australian Shepherd (and Mini) About 50% Mostly carriers; about 9% M/M in a study of 145 dogs
Long-haired Whippet About 50% Same mutation, inherited from the Collie lineage
McNab About 30% Fewer dogs tested than in AKC breeds
Silken Windhound About 30% Same mutation, inherited from the Collie lineage
Shetland Sheepdog About 15% Much higher in Europe and the UK than in the US or Japan
English Shepherd About 15% Mostly carriers
German Shepherd About 10% Found mainly in white dogs or dogs with white ancestry
Old English Sheepdog About 5% Mostly carriers
Border Collie Low (not calculated by WSU) Mutant allele frequency below 1% in most countries studied

These numbers should alarm every Collie owner. In practical terms, if you pick three Rough Collies at random, one of them is likely homozygous for the mutation. That dog cannot safely receive ivermectin at the high doses used against mange, loperamide at any dose, or multiple other common medications without significant risk of severe neurological toxicity. Collie owners in particular should review the documented drug reaction cases in Collies to understand the real-world consequences of untested medication use.

The table above covers the highest-prevalence breeds, but it is far from the full picture: moderate and low-prevalence breeds, and the mixed-breed crosses that inherit the mutation from a single herding-breed ancestor, carry real risk too. Our complete MDR1 breed prevalence guide breaks down every risk category in detail.

The Inheritance Pattern

MDR1 follows autosomal recessive inheritance for severe toxicity, but the clinical picture is more nuanced than simple Mendelian genetics would suggest. Dogs with one mutant copy (N/M) are not simply carriers who can be treated as normal dogs.

Colley resting at home
  • N/N (Normal/Normal): Full P-gp function. Can receive all medications at standard doses.
  • N/M (Normal/Mutant): Reduced, not absent, P-gp function (an intermediate phenotype). May show increased sensitivity to high doses of substrate drugs. Should avoid loperamide entirely, as WSU advises for every dog with the mutation, and should not receive high-dose ivermectin protocols without veterinary advice.
  • M/M (Mutant/Mutant): No functional P-gp. Cannot safely receive any substrate drugs at standard doses. Many drugs must be avoided entirely.

Why N/M Dogs Need Careful Management

Early publications suggested that only M/M dogs were at risk. This is incorrect. N/M dogs show an intermediate sensitivity that becomes clinically relevant with high-dose protocols, such as the ivermectin doses used against demodectic mange, and with chemotherapy drugs such as vincristine, vinblastine and doxorubicin, where carriers can clear the drug more slowly and develop bone marrow suppression. N/M status is not a free pass.

The Blood-Brain Barrier Problem

To understand why MDR1 matters, you need to understand the blood-brain barrier (BBB). This specialized structure consists of endothelial cells connected by tight junctions, preventing most blood-borne substances from entering brain tissue. P-gp is a critical component of this barrier.

When a P-gp substrate drug enters the brain capillaries, functional P-gp proteins recognize it and pump it back into the bloodstream. In animals lacking functional P-gp, these drugs accumulate in brain tissue: mice without the equivalent gene became about 100 times more sensitive to ivermectin, with drug levels raised especially in the brain (Schinkel and colleagues, Cell, 1994), and M/M dogs show the same vulnerability.

The neurological effects of this accumulation depend on the specific drug. Ivermectin and related compounds enhance inhibitory GABA signaling, causing sedation, ataxia, tremors, blindness, coma, and death. The mechanism is essentially overstimulation of GABA-A receptors in the central nervous system, similar to severe benzodiazepine overdose but without a readily available antidote. The team at Ivermectin Sensitivity has published an excellent breakdown of these pharmacological pathways in MDR1 dogs.

Why Testing Matters

There is no excuse not to test a herding breed dog for MDR1. The test costs between $45 and $75 depending on the laboratory, requires only a cheek swab, and provides results valid for the dog's lifetime. Once you know your dog's status, you can ensure that anesthesia protocols are properly adjusted for any surgical procedure and that flea and tick products are MDR1-compatible. A single emergency veterinary visit for drug toxicity will cost thousands of dollars and may not save your dog's life.

Border Collie portrait

I test all my relatives' dogs for free through my laboratory. I have given cheek swab kits as gifts. I have cornered people at dog parks to hand them testing information. I do this because I have held dying dogs whose owners did not know any better, and I never want to see it again.

For detailed information on testing laboratories, costs, and how to interpret results, read our Testing Options guide. For the specific drugs to avoid, see our Complete Drug Avoidance List.

The Bigger Picture

MDR1 is part of a broader pattern of inherited conditions in herding breeds. These dogs share common ancestry, and that ancestry carries multiple genetic variants beyond MDR1. Understanding MDR1 in isolation is helpful, but understanding it as part of the broader landscape of herding breed genetics provides essential context for comprehensive health management.

Responsible ownership of a herding breed means accepting that these dogs require genetic testing and informed medication management. It is not optional. It is not paranoid. It is the basic standard of care that every Australian Shepherd, Collie, and Sheltie deserves. For those interested in what the future may hold, gene therapy research is exploring ways to restore P-glycoprotein function in affected dogs, though a clinical treatment remains years away.

Dr. Sarah Mitchell, DVM

Veterinary Pharmacologist